.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Thermo Fisher Scientific recently announced a major microbiology business sale to private equity firm Astorg. This deal carries a value of approximately $1.08 billion. Consequently, the transaction includes cash and a $50 million seller note. This specific unit provides antimicrobial susceptibility testing and culture media products. These tools are essential for clinical, pharmaceutical, and food safety applications.
The unit belongs to the specialty diagnostics segment at Thermo Fisher. Furthermore, it generated $645 million in revenue during 2025. This divestiture allows the company to manage its portfolio more actively. Therefore, they can deploy capital to create higher shareholder value. However, the transaction will likely reduce adjusted earnings initially. Specifically, the company expects a $0.15 impact per share in the first full year after the close.
The company expects the sale to close in the second half of 2026. Consequently, medical professionals in India should monitor potential changes in product availability. Astorg is a well-known private equity firm with a history of scaling healthcare assets. Thus, this transition might lead to new investments in the microbiology sector. Additionally, Thermo Fisher will provide more financial details during their next earnings call.
Q1: What does the Thermo Fisher microbiology business produce?
The unit supplies antimicrobial susceptibility testing and culture media products used in clinical, pharmaceutical, and food safety settings.
Q2: When will the transaction between Thermo Fisher and Astorg be finalized?
The companies expect the deal to close during the second half of 2026, pending regulatory approvals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Thermo Fisher Scientific is selling its microbiology business to Astorg for $1.08 billion to focus on specialty diagnostics and shareholder value....
5 months ago
The TREM-AB open-label pilot study evaluated a wearable passive nonlinear vibration absorber for essential tremor. The Nonlinear Energy Sink bracelet reduced clinical Fahn-Tolosa-Marin tremor scores by 32.1% and electrophysiological tremor power by 49.2% with no adverse effects reported.
Today
A population-based study of 20,928 children reveals that small vulnerable newborns face sex-divergent mental capital outcomes at ages 6-7: term SGA girls show higher behavioral difficulties and lower resilience, while preterm non-SGA boys experience increased behavioral problems.
Today
A landmark study details how an enterprise pediatric remote patient management model expanded from a single cardiology pilot to 16 diverse specialty programs by combining centralized digital operations with specialty clinical leadership.
Today
A comparative review of tension band wiring and intramedullary screw fixation in thumb metacarpophalangeal arthrodesis, evaluating union rates, hardware complications, and clinical outcomes.
Today
A breakthrough ultrathin multimodal sensor decouples physical hemodynamic monitoring from disposable electrochemical calibration, achieving long-term wearable glucose prediction with 81.36% accuracy and a 9.12% MARD. This offers a robust, drift-free solution for outpatient metabolic surveillance.
Today
